1. At a Glance – The MNC With a Shrinking Waistline
Sanofi India Ltd is trading at ₹3,965, with a market cap of ₹9,132 crore. The stock has fallen -9.63% in 3 months and -20.9% in 1 year, clearly reminding shareholders that even insulin cannot treat falling stock prices.
On the numbers side:
- Q4 CY25 Sales: ₹420 crore (↓18.5% YoY)
- Q4 PAT: ₹61.7 crore (↓27.7% YoY)
- Full Year CY25 Sales: ₹1,837 crore
- Full Year PAT: ₹327 crore
- ROCE: 57.5%
- ROE: 43%
- Dividend Yield: 2.95%
- Debt to Equity: 0.02 (basically debt-free)
- Stock P/E: 26.4
- Book Value: ₹326 (trading at 12.2x book)
So what do we have here?
A highly profitable MNC with declining sales, shrinking exports, aggressive dividend payouts, and a “pivotal transformation” narrative.
Is this a turnaround story… or just a company slimming down faster than a New Year resolution?
Let’s dissect.
2. Introduction – From Pharma Giant to Portfolio Surgeon
Sanofi India follows the calendar year as its financial year. That’s right — while most Indian companies talk March, Sanofi talks December. Because multinational vibes.
Promoters (Sanofi Global and Hoechst GmbH) hold 60.40%, unchanged. So the French parents are still fully committed.
Now here’s where the drama begins.
In recent years, Sanofi:
- Sold the Ankleshwar plant for ₹320.68 crore
- Divested its nutraceutical division for ₹587 crore
- Demerged its Consumer Healthcare business in June 2024 (1:1 share swap)
So what remains?
Primarily:
- Diabetes
- Cardiology
- CNS
- Partnership model products
Translation: They’ve been chopping limbs to save the torso.
Sales over 5 years?
-8.74% CAGR.
Profit growth over 5 years?
-7.38%.
But ROE?
Still north of 40%.
How is profit strong while sales shrink?
Cost discipline. Divestments. Dividend engineering. Classic MNC playbook.
But here’s the question:
Is this restructuring creating future growth — or just preserving margins on a smaller pie?
3. Business Model – WTF Do They Even Do?
Sanofi India is a multinational pharma marketing and manufacturing company.
They operate:
- One Goa manufacturing plant (5+ billion tablets capacity, 85% utilization)
- 12 Contract Manufacturing Organizations (CMOs)
- Export presence in 28+ countries
Key therapy focus:
- Diabetes (Lantus, Toujeo, Soliqua, Insutage)
- Cardiology
- CNS
- Oral anti-diabetes
Revenue mix CY23:
- 93% products
- 6% services
- 1% others
Exports form 19% of revenues (61% of Goa production is for exports).
But in Q4 CY25?
Exports dropped sharply. Domestic was flat-ish.
They’ve now pivoted to a “Partnership Model”:
- Tie-up with Cipla for CNS (5 years)
- Tie-up with Emcure for CV (5 years)
So instead of heavy in-house selling, they are leveraging Indian pharma muscle.
Smart move? Possibly.
Desperate move? Maybe.
Over 21% of portfolio priced below ₹5 per
